Study of DF6215 in Patients With Advanced Solid Tumors

Study of DF6215 in Patients With Advanced Solid Tumors

Conditions: Solid Tumor, Adult; Solid Tumor Cancer
Interventions: Drug: DF6215; Drug: pembrolizumab; Drug: KEYTRUDA®
Sponsors: Dragonfly Therapeutics; Merck Sharp & Dohme LLC
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 19, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments